7 results on '"Evans, Alison A."'
Search Results
2. Tackling gaps in developing life‐changing treatments for dementia
- Author
-
Mauricio, Rui, Benn, Caroline, Davis, John, Dawson, Gerry, Dawson, Lee A, Evans, Alison, Fox, Nick, Gallacher, John, Hutton, Mike, Isaac, John, Jones, Declan NC, Jones, Lesley, Lalli, Giovanna, Libri, Vincenzo, Lovestone, Simon, Moody, Catherine, Noble, Wendy, Perry, Hugh, Pickett, James, Reynolds, David, Ritchie, Craig, Rohrer, Jonathan D, Routledge, Carol, Rowe, James, Snyder, Heather, Spires-Jones, Tara, Swartz, Jina, Truyen, Luc, Whiting, Paul, Therapeutics for Dementia Consortium, Rowe, James [0000-0001-7216-8679], and Apollo - University of Cambridge Repository
- Subjects
0301 basic medicine ,media_common.quotation_subject ,Review Article ,Disease ,Target validation ,03 medical and health sciences ,Clinical trials ,0302 clinical medicine ,Diagnosis ,medicine ,Dementia ,Disease-modifying treatment ,Earlier detection ,Neurodegeneration ,Genetic risk ,media_common ,Medical education ,geography ,Summit ,geography.geographical_feature_category ,Alzheimer's disease ,medicine.disease ,3. Good health ,Clinical trial ,Psychiatry and Mental health ,030104 developmental biology ,Action plan ,Genetic risk factors ,Neurology (clinical) ,Psychological resilience ,Psychology ,030217 neurology & neurosurgery ,Dementia research - Abstract
Since the G8 dementia summit in 2013, a number of initiatives have been established with the aim of facilitating the discovery of a disease-modifying treatment for dementia by 2025. This report is a summary of the findings and recommendations of a meeting titled “Tackling gaps in developing life-changing treatments for dementia”, hosted by Alzheimer's Research UK in May 2018. The aim of the meeting was to identify, review, and highlight the areas in dementia research that are not currently being addressed by existing initiatives. It reflects the views of leading experts in the field of neurodegeneration research challenged with developing a strategic action plan to address these gaps and make recommendations on how to achieve the G8 dementia summit goals. The plan calls for significant advances in (1) translating newly identified genetic risk factors into a better understanding of the impacted biological processes; (2) enhanced understanding of selective neuronal resilience to inform novel drug targets; (3) facilitating robust and reproducible drug-target validation; (4) appropriate and evidence-based selection of appropriate subjects for proof-of-concept clinical trials; (5) improving approaches to assess drug-target engagement in humans; and (6) innovative approaches in conducting clinical trials if we are able to detect disease 10–15 years earlier than we currently do today.
- Published
- 2019
3. Spontaneous Seroconversion in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Implications for Interferon Therapy
- Author
-
Evans, Alison A., Fine, Manette, and London, W. Thomas
- Published
- 1997
4. Mild Cognitive Impairment: the Manchester consensus.
- Author
-
Dunne, Ross A, Aarsland, Dag, O'Brien, John T, Ballard, Clive, Banerjee, Sube, Fox, Nick C, Isaacs, Jeremy D, Underwood, Benjamin R, Perry, Richard J, Chan, Dennis, Dening, Tom, Thomas, Alan J, Schryer, Jeffrey, Jones, Anne-Marie, Evans, Alison R, Alessi, Charles, Coulthard, Elizabeth J, Pickett, James, Elton, Peter, and Jones, Roy W
- Subjects
AMYLOID beta-protein precursor ,BIOMARKERS ,CEREBRAL circulation ,CONSENSUS (Social sciences) ,NEURORADIOLOGY ,MILD cognitive impairment - Abstract
Given considerable variation in diagnostic and therapeutic practice, there is a need for national guidance on the use of neuroimaging, fluid biomarkers, cognitive testing, follow-up and diagnostic terminology in mild cognitive impairment (MCI). MCI is a heterogenous clinical syndrome reflecting a change in cognitive function and deficits on neuropsychological testing but relatively intact activities of daily living. MCI is a risk state for further cognitive and functional decline with 5–15% of people developing dementia per year. However, ~50% remain stable at 5 years and in a minority, symptoms resolve over time. There is considerable debate about whether MCI is a useful clinical diagnosis, or whether the use of the term prevents proper inquiry (by history, examination and investigations) into underlying causes of cognitive symptoms, which can include prodromal neurodegenerative disease, other physical or psychiatric illness, or combinations thereof. Cognitive testing, neuroimaging and fluid biomarkers can improve the sensitivity and specificity of aetiological diagnosis, with growing evidence that these may also help guide prognosis. Diagnostic criteria allow for a diagnosis of Alzheimer's disease to be made where MCI is accompanied by appropriate biomarker changes, but in practice, such biomarkers are not available in routine clinical practice in the UK. This would change if disease-modifying therapies became available and required a definitive diagnosis but would present major challenges to the National Health Service and similar health systems. Significantly increased investment would be required in training, infrastructure and provision of fluid biomarkers and neuroimaging. Statistical techniques combining markers may provide greater sensitivity and specificity than any single disease marker but their practical usefulness will depend on large-scale studies to ensure ecological validity and that multiple measures, e.g. both cognitive tests and biomarkers, are widely available for clinical use. To perform such large studies, we must increase research participation amongst those with MCI. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. What matters to people with memory problems, healthy volunteers and health and social care professionals in the context of developing treatment to prevent Alzheimer's dementia? A qualitative study.
- Author
-
Watson, Julie, Clarke, Charlotte, Saunders, Stina, Muniz Terrera, Graciela, Ritchie, Craig, Luz, Saturnino, and Evans, Alison
- Subjects
ALZHEIMER'S disease prevention ,MEMORY disorders ,ATTITUDE (Psychology) ,CLINICAL trials ,FOCUS groups ,GROUP identity ,INTERPERSONAL relations ,INTERVIEWING ,MEDICAL personnel ,HEALTH outcome assessment ,QUALITY of life ,RESEARCH funding ,STATISTICAL sampling ,QUALITATIVE research ,SOCIOECONOMIC factors ,WELL-being ,DATA analysis software ,PATIENTS' attitudes ,SOCIAL worker attitudes ,PREVENTION - Abstract
Background: Alzheimer's disease (AD) is recognized as one of the greatest global public health challenges. There is increasing consensus that optimal disease modification using pharmaceuticals may best be achieved earlier in the disease continuum before symptoms occur. However, more needs to be understood about what outcomes are meaningful to potential participants in clinical trials within this preventative paradigm and how people make trade‐offs between risks and benefits. The Electronic Person‐Specific Outcome Measure (ePSOM) programme is developing an app to capture person‐specific outcomes and preferences in clinical trials. Objective: As one phase in the ePSOM programme, this study explored what matters when developing new treatments to prevent AD and how trade‐offs are made between risks and benefits, from three perspectives. Design: Focus groups were conducted with people living with memory problems (n = 21) and healthy volunteers (n = 10), and telephone interviews with health and social care professionals (n = 10). Differences and overlap between the three groups were explored. Results: Outcomes that matter lie in five key domains in relation to what matters in everyday life: Everyday Functioning; Relationships and Social Connections; Enjoying Life; Sense of Identity; and Alleviating Symptoms. Insights were gained into the significance of reducing the risk of developing dementia with drugs and the processes of weighing up risks versus benefits. Discussion and conclusions: The key domains identified are being used to inform the next stage of the ePSOM programme which is to develop a survey to be distributed nationally in the UK to explore these issues further. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Study protocol for a randomized controlled trial comparing mindfulness-based cognitive therapy with maintenance anti-depressant treatment in the prevention of depressive relapse/recurrence: the PREVENT trial.
- Author
-
Kuyken, Willem, Byford, Sarah, Byng, Richard, Dalgleish, Tim, Lewis, Glyn, Taylor, Rod, Watkins, Edward R., Hayes, Rachel, Lanham, Paul, Kessler, David, Morant, Nicola, and Evans, Alison
- Subjects
MENTAL depression ,THERAPEUTICS ,DEPRESSED persons ,CLINICAL trials ,MEDICAL care ,MENTAL health - Abstract
Background: Depression is a common and distressing mental health problem that is responsible for significant individual disability and cost to society. Medication and psychological therapies are effective for treating depression and maintenance anti-depressants (m-ADM) can prevent relapse. However, individuals with depression often express a wish for psychological help that can help them recover from depression in the long-term. We need to develop psychological therapies that prevent depressive relapse/recurrence. A recently developed treatment, Mindfulness-based Cognitive Therapy (MBCT, see http://www.mbct.co.uk) shows potential as a brief group programme for people with recurring depression. In two studies it has been shown to halve the rates of depression recurring compared to usual care. This trial asks the policy research question, is MBCT superior to m-ADM in terms of: a primary outcome of preventing depressive relapse/recurrence over 24 months; and, secondary outcomes of (a) depression free days, (b) residual depressive symptoms, (c) antidepressant (ADM) usage, (d) psychiatric and medical co-morbidity, (e) quality of life, and (f) cost effectiveness? An explanatory research question asks is an increase in mindfulness skills the key mechanism of change? Methods/Design: The design is a single blind, parallel RCT examining MBCT vs. m-ADM with an embedded process study. To answer the main policy research question the proposed trial compares MBCT plus ADM-tapering with m-ADM for patients with recurrent depression. Four hundred and twenty patients with recurrent major depressive disorder in full or partial remission will be recruited through primary care. Depressive relapse/recurrence over two years is the primary outcome variable. The explanatory question will be addressed in two mutually informative ways: quantitative measurement of potential mediating variables pre/post-treatment and a qualitative study of service users' views and experiences. Discussion: If the results of our exploratory trial are extended to this definitive trial, MBCT will be established as an alternative approach to maintenance anti-depressants for people with a history of recurrent depression. The process studies will provide evidence about the effective components which can be used to improve MBCT and inform theory as well as other therapeutic approaches. Trial registration number: ISRCTN26666654 [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
7. HeSANDA Guiding Principles
- Author
-
Kang, Kristan, Askie, Lisa, Boughtwood, Tiffany, Boyle, Douglas, Connelly, Luke, Kannan, Anitha, Nielsen, Manuel, Vajdic, Claire, Willson, Melina, Evans, Alison, Henwood, Jen, and Nemeh, Fiona
- Subjects
Data Sharing ,Clinical Trials ,Australia - Abstract
A set of principles informed by the requirements of the clinical trials research community and health consumers to guide the development of health data sharing infrastructure under the HeSANDA program.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.